Morgan Stanley’s Dermata Therapeutics DRMA Stock Holding History

Morgan Stanley’s Portfolio DRMA Stock Details DRMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3	Buy	+2	New	+$3	﹤0.01%	8374
2023 Q1	–	Hold	0	–	-$230	–	7741
2022 Q4	–	Hold	0	–	–	–	7630
2022 Q2	–	Hold	0	–	–	–	7837
2022 Q1	–	Hold	0	–	–	–	7989
2021 Q4	–	Hold	0	–	–	–	7856

Other funds holding DRMA

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Morgan Stanley's DRMA Position: Q2 2026 in Review

Morgan Stanley opened a new position in Dermata Therapeutics (DRMA) in Q2 2026: 2 shares worth $3. The stake represents ﹤0.01% of the portfolio and ranks #8374 among its holdings.

13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

Morgan Stanley held 2 shares of Dermata Therapeutics worth $3 as of Q2 2026.
Dermata Therapeutics was a new Morgan Stanley position in Q2 2026.
Dermata Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #8374 holding.
13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.